Literature DB >> 1420693

AIDS enteropathy.

J G Bartlett1, P C Belitsos, C L Sears.   

Abstract

Chronic diarrhea is one of the hallmarks of advanced human immunodeficiency virus (HIV) disease. The symptoms of this complication are troublesome, have a significant impact on the patient's quality of life, and in severe cases can lead to extreme abnormalities in fluids and electrolytes and can even cause death. The workup for AIDS-associated diarrhea is often frustrating and frequently unrewarding. However, during the last 10 years, much has been learned about the causes of diarrhea; while treatment is still often ineffective, some advances have been made. Dr. John G. Bartlett and his colleagues in the Department of Medicine at Johns Hopkins University School of Medicine have been responsible for many of these advances. In this AIDS Commentary, these experts discuss recent advances that have enhanced our understanding of chronic diarrhea in HIV-infected persons and offer their recommendations for the most efficient and effective approach to managing these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1420693     DOI: 10.1093/clind/15.4.726

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Infectious diarrhoea in antiretroviral therapy-naive HIV/AIDS patients in Kenya.

Authors:  Jane W Wanyiri; Henry Kanyi; Samuel Maina; David E Wang; Paul Ngugi; Roberta O'Connor; Timothy Kamau; Tabitha Waithera; Gachuhi Kimani; Claire N Wamae; Mkaya Mwamburi; Honorine D Ward
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-10       Impact factor: 2.184

2.  Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.

Authors:  R C Owens; K B Patel; M A Banevicius; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 3.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

4.  Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.

Authors:  M K Lacy; D P Nicolau; C H Nightingale; A Geffken; R Teng; J Vincent; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  HEp-2 cell adherence patterns, serotyping, and DNA analysis of Escherichia coli isolates from eight patients with AIDS and chronic diarrhea.

Authors:  Y Polotsky; J P Nataro; D Kotler; T J Barrett; J M Orenstein
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

6.  Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum.

Authors:  L van der Hoek; R Boom; J Goudsmit; F Snijders; C J Sol
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS.

Authors:  D E Nilssen; F Müller; O Oktedalen; S S Frøland; O Fausa; T S Halstensen; P Brandtzaeg
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Fatal dual infection with Salmonella and Mycobacterium avium complex infection in a patient with advanced acquired immunodeficiency syndrome: a case report.

Authors:  Adetunji Adejumo; Olutayo Olabige; Vel Sivapalan
Journal:  Cases J       Date:  2009-09-11

9.  Differential effect of the immunomodulatory hormone somatostatin on replication of human immunodeficiency virus type 1 in CD4+ and CD8+ T lymphocytes.

Authors:  L Mercure; D Phaneuf; M A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

10.  Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor.

Authors:  J Fantini; D G Cook; N Nathanson; S L Spitalnik; F Gonzalez-Scarano
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.